Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Medical Genetics · Hypoinsulinemic Hypoglycemia With Hemihypertrophy

Tumor Screening & Long-Term Monitoring

At a Glance

Children with hemihypertrophy and related overgrowth may need diagnosis-specific abdominal ultrasounds and age-adjusted AFP blood tests because of kidney and liver tumor risk. In infants, AFP is naturally high, so doctors follow its trend over time.

When a child has both overgrowth and low blood sugar, the medical focus often shifts toward long-term monitoring. The same genetic pathways that affect growth and sugar can also increase the risk for specific childhood tumors.

While the risk of a tumor is statistically small, proactive screening reduces risk, though it does not guarantee a tumor is absent [1][2].

Understanding the Tumor Connection

The primary concern in overgrowth conditions like Beckwith-Wiedemann Spectrum (BWSp) or isolated lateralized overgrowth is the development of specific tumors:

  • Wilms Tumor: A type of kidney cancer [1].
  • Hepatoblastoma: A rare liver cancer [3].

These tumors are linked to the same signaling that causes hemihypertrophy (one-sided overgrowth) [4]. Because these cells are already primed to grow faster than normal, they are more susceptible [5].

The Surveillance Schedule: Diagnosis-Specific

The need for surveillance, the organs tested, and the stopping ages vary by molecular subtype and country. Do not assume the schedule is identical for every child. Direct families to a genetics specialist for a diagnosis-specific protocol.

  1. Abdominal/Renal Ultrasounds: Often performed every 3 months in specific BWSp/overgrowth frameworks to check the kidneys and liver [1][6].
  2. AFP Blood Tests: The Alpha-fetoprotein (AFP) test is used to screen for hepatoblastoma in certain cohorts [3][7].

The “High” AFP Trap: Why Age Matters

One of the most stressful parts of monitoring an infant is receiving a “high” AFP result. It is vital to know that AFP is naturally very high in all newborns and remains elevated for most of the first year of life [8][9].

Doctors must interpret these results using age-adjusted curves [8]. Instead of looking at a single number, they look for a “downward trend” [10]. If the numbers are dropping as the child gets older, it is generally reassuring.

Long-Term Metabolic Health

As children with AKT2 or PIK3CA mutations grow, their hypoglycemia (low blood sugar) may change.

  • Potential Remission: Some children see an improvement in their blood sugar stability as they reach school age [4][11].
  • The “Metabolic Shift”: There is a theoretical risk of metabolic issues later in life, such as insulin resistance or changes in body fat distribution (adiposity) [12].
  • Developmental Follow-up: Regular neurodevelopmental check-ups are recommended to ensure the child is meeting milestones and to provide support for any learning challenges [13][14].

Coping with “Scanxiety”

Living in increments creates a unique emotional burden known as scanxiety—the intense anxiety felt leading up to and during medical screenings.

  • It is Normal: Feeling hyper-vigilant about your child’s health is a natural response.
  • The Goal is Peace of Mind: Remember that the scans are designed to be a “safety net.” [1].
  • Build a Routine: Many families find it helpful to plan a small “reward” after each screening.

Regular coordination between your geneticist, oncologist (if indicated), and endocrinologist will ensure the surveillance plan is tailored to your child’s specific genetic variant [5].

Common questions in this guide

Why are children with hemihypertrophy or Beckwith-Wiedemann spectrum screened for tumors?
Some overgrowth conditions increase the chance of Wilms tumor, a kidney cancer, and hepatoblastoma, a liver cancer. Regular screening can help doctors find concerning changes early, but it cannot guarantee that a tumor is absent.
How often does my child need an ultrasound?
The schedule depends on your child's molecular diagnosis, the organs at risk, and local guidance. Some Beckwith-Wiedemann spectrum and overgrowth protocols use abdominal or kidney ultrasounds about every three months, but a genetics specialist should set the plan.
Does a high AFP level mean my infant has liver cancer?
Not necessarily. AFP is naturally very high in newborns and stays elevated during much of the first year, so doctors compare the result with age-adjusted ranges and follow whether it is falling over time.
When can my child's tumor surveillance stop?
The stopping age and whether ultrasound or AFP testing is needed vary by molecular subtype and country. Ask your child's genetics specialist for the schedule specific to the diagnosis rather than relying on a general age.
Can my child's low blood sugar improve as they grow?
Some children with AKT2- or PIK3CA-related overgrowth have more stable blood sugar by school age. Later follow-up may still watch for insulin resistance or changes in body-fat distribution, and regular developmental checks can identify learning support needs.
What symptoms should I report between screening visits?
Contact your child's care team about a new firm abdominal lump, blood in the urine, or unexplained fevers rather than waiting for the next screening visit. These signs can have many causes, but they deserve prompt medical assessment.
How can our family cope with anxiety before each scan?
Anxiety before screening is common, and it may help to treat appointments as a predictable routine. Ask the care team about emotional support and plan a small, reassuring activity or reward after each scan.

Get notified when new evidence is published on Hypoinsulinemic hypoglycemia and body hemihypertrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    [Tumor predisposition syndromes and nephroblastoma : Early diagnosis with imaging].

    Welter N, Furtwängler R, Schneider G, et al.

    Radiologie (Heidelberg, Germany) 2022; (62(12)):1033-1042 doi:10.1007/s00117-022-01056-w.

    PMID: 36008692
  2. 2

    The effectiveness of Wilms tumor screening in Beckwith-Wiedemann spectrum.

    Mussa A, Duffy KA, Carli D, et al.

    Journal of cancer research and clinical oncology 2019; (145(12)):3115-3123 doi:10.1007/s00432-019-03038-3.

    PMID: 31583434
  3. 3

    Beckwith-Wiedemann spectrum (BWSp): an update on diagnosis, management, and follow-up from the scientific committee of the Italian BWSp association.

    Russo S, Milani D, Meossi C, et al.

    Italian journal of pediatrics 2025; (51(1)):287 doi:10.1186/s13052-025-02131-3.

    PMID: 41126215
  4. 4

    Treatment of hypoglycemia due to a rare pathogenic variant in AKT2 with waxy maize heat-modified starch.

    Parker M, Yau D

    Clinical case reports 2024; (12(2)):e8473 doi:10.1002/ccr3.8473.

    PMID: 38344362
  5. 5

    Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement.

    Brioude F, Kalish JM, Mussa A, et al.

    Nature reviews. Endocrinology 2018; (14(4)):229-249 doi:10.1038/nrendo.2017.166.

    PMID: 29377879
  6. 6

    Wilms tumour in Beckwith-Wiedemann Syndrome and loss of methylation at imprinting centre 2: revisiting tumour surveillance guidelines.

    Brzezinski J, Shuman C, Choufani S, et al.

    European journal of human genetics : EJHG 2017; (25(9)):1031-1039 doi:10.1038/ejhg.2017.102.

    PMID: 28699632
  7. 7

    Defining an optimal time window to screen for hepatoblastoma in children with Beckwith-Wiedemann syndrome.

    Mussa A, Duffy KA, Carli D, et al.

    Pediatric blood & cancer 2019; (66(1)):e27492 doi:10.1002/pbc.27492.

    PMID: 30270492
  8. 8

    Improving clinical interpretation of serum alpha-fetoprotein in children: using continuous and discrete reference intervals.

    Tran DM, Phan PH, Cao TV, et al.

    Clinical chemistry and laboratory medicine 2026; (64(8)):1838-1848 doi:10.1515/cclm-2026-0262.

    PMID: 41996693
  9. 9

    Role of Alpha-Fetoprotein (AFP) in Diagnosing Childhood Cancers and Genetic-Related Chronic Diseases.

    Głowska-Ciemny J, Szymanski M, Kuszerska A, et al.

    Cancers 2023; (15(17)) doi:10.3390/cancers15174302.

    PMID: 37686577
  10. 10

    Serum α-fetoprotein in pediatric oncology: not a children's tale.

    Ferraro S, Panzeri A, Braga F, Panteghini M

    Clinical chemistry and laboratory medicine 2019; (57(6)):783-797 doi:10.1515/cclm-2018-0803.

    PMID: 30367785
  11. 11

    Successful Treatment of Hypoglycemia With Alpelisib in Pediatric Patients With PIK3CA-Related Overgrowth Spectrum.

    Nasomyont N, Rutter MM, Backeljauw PF

    JCEM case reports 2023; (1(2)):luad027 doi:10.1210/jcemcr/luad027.

    PMID: 37908459
  12. 12

    A girl with CLOVES syndrome with a recurrent PIK3CA somatic mutation and pancreatic steatosis.

    Hanafusa H, Morisada N, Nomura T, et al.

    Human genome variation 2019; (6()):31 doi:10.1038/s41439-019-0063-9.

    PMID: 31263565
  13. 13

    A More Precise Description of the AKT2-Related Hypoinsulinemic Hypoglycemia and Overgrowth Syndrome Phenotype, Formerly Described Under the MORFAN Acronym.

    Turnovec M, Bubeníková A, Rýdlo O, et al.

    American journal of medical genetics. Part A 2026; (200(8)):1890-1896 doi:10.1002/ajmg.a.70138.

    PMID: 41869744
  14. 14

    Clinical and neuroimaging findings in 33 patients with MCAP syndrome: A survey to evaluate relevant endpoints for future clinical trials.

    Garde A, Guibaud L, Goldenberg A, et al.

    Clinical genetics 2021; (99(5)):650-661 doi:10.1111/cge.13918.

    PMID: 33415748

This page is for informational purposes only and does not constitute medical advice. Your child's genetics specialist and care team should determine and interpret tumor surveillance and long-term monitoring based on the specific diagnosis.

Guide contents Hypoinsulinemic hypoglycemia and body hemihypertrophy
Research & Literature
04 Treatment and Daily Management 06 Building Your Child's Care Team